Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Resolvyx Pharmaceuticals

Request full access

Resolvyx Pharmaceuticals develops therapeutics with small molecule lipid mediators for the treatment of inflammatory diseases

Cambridge, United StatesFounded 2001Biotech & Life Sciences

About Resolvyx Pharmaceuticals

Resolvyx Pharmaceuticals focuses on developing innovative therapies that target inflammation and immune responses to treat chronic diseases. The company operates in the biopharmaceutical sector, aiming to address unmet medical needs in conditions such as asthma, cardiovascular diseases, and neurodegenerative disorders. Resolvyx's business model revolves around research and development, leveraging proprietary technology to create novel drug candidates. Revenue is generated through partnerships, licensing agreements, and potential future product sales. The primary clients include healthcare providers, pharmaceutical companies, and research institutions. The market is highly competitive, with a strong emphasis on scientific innovation and regulatory compliance.

Source: Dealroom company data

At a glance

Status
Operational
Employees
2
Open positions
None listed
Dealroom signal
54.8/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VC✓Equity / VC Nov 2010 $2.5M $125M Undisclosed —
DEBT✓Debt Jun 2010 $1.2M — Undisclosed —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Resolvyx Pharmaceuticals website traffic

Latest recorded traffic for Resolvyx Pharmaceuticals is 210 monthly website visits. Resolvyx Pharmaceuticals's team grew 0% over the past year.

Latest monthly visits210 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Mirexus Biotechnologies, Inc.Corn-based phytoglycogen nanoparticles for cosmetic and personal care Kitchener, Canada Operational 9 $18M —
Aperiam BioTaking the guesswork out of biotechnology with computer vision that illuminates critical parts of protein chemistry New York City, United States Operational
LucencePrecision oncology company dedicated to creating state-of-the-art, highly sensitive liquid biopsy tests for early disease detection and personalized treatment selection Palo Alto, United States Operational
Dyno TherapeuticsUtilizing next-gen DNA technologies and machine learning to engineer AAV capsids for effective delivery of gene therapies Watertown, United States Operational
Iota BiosciencesDeveloping a platform to empower the future of bioelectronic medicine Berkeley, United States Acquired
GenEditDeveloping innovative therapies through targeted delivery of genetic medicines Brisbane, United States Operational
CrystalplexA biochemistry and diagnostics laboratory, specializing in nanotechnology for the life sciences industry Pittsburgh, United States Operational
Xalud TherapeuticsDiscovers, develops, and provides novel treatments for chronic inflammatory diseases that can dramatically improve the health and quality of life for millions of suffering patients New York City, United States Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Resolvyx Pharmaceuticals in the Cambridge ecosystem

Live from Dealroom

The Resolvyx Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A7 investors entered at this stage

Other known investors2 additional known investors

  • Brigham and Women's Hospital
  • Harvard Medical School
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Resolvyx Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Resolvyx Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.